by
Gus Iversen, Editor in Chief | May 19, 2026
Boston Scientific has agreed to invest $1.5 billion in MiRus LLC for an approximately 34% equity stake and secured an exclusive option to acquire the company’s investigational transcatheter aortic valve replacement platform.
The Marlborough, Massachusetts-based medtech company said the agreement centers on MiRus’ SIEGEL balloon-expandable TAVR system, a nickel-free valve built with a proprietary rhenium alloy frame. MiRus, which is based in Atlanta, is developing the device for patients with severe aortic stenosis.
Under the deal, Boston Scientific can acquire the MiRus TAVR business through additional payments totaling $3 billion if specified clinical and regulatory milestones are met. The agreement also includes potential future milestone-based payments tied to net sales of the valve and an option to acquire MiRus’ mitral and tricuspid valve replacement assets.
Ad Statistics
Times Displayed: 6679
Times Visited: 20 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
The SIEGEL valve uses dry porcine tissue leaflets and a nitric oxide-coated rhenium frame. According to the companies, the material is intended to provide greater radial strength than cobalt or titanium while avoiding nickel exposure. The valve’s open-cell frame design is intended to reduce foreshortening during deployment and support more precise positioning.
MiRus said the device is pre-mounted on the balloon catheter and can be delivered through an 8 French expandable sheath across all valve sizes. The company said the smaller delivery profile could reduce vascular complications associated with TAVR procedures.
MiRus recently launched the STAR pivotal trial, which plans to enroll up to 1,025 patients with severe symptomatic aortic stenosis across low-, intermediate- and high-surgical-risk categories. The study is evaluating the safety and effectiveness of the 23 mm, 26 mm and 29 mm valve sizes.
“The occurrence and recognition of aortic stenosis is growing rapidly and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio,” said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies at Boston Scientific.
The SIEGEL TAVR system remains investigational and has not received regulatory approval for commercial use in any country.
